In a victory for research advocates, on December 13, President Barack Obama signed the 21st Century Cures Act into law.
Fast Track is a process designed to expedite FDA review and get important new drugs to the patient earlier.
Over a year of advocacy efforts have paid off as the bill now moves to the President for signature.
Lupus is the feature of a new publication by the largest non-profit alliance committed to making medical research a national priority.
This week, LFA-supported researchers will share results of a study that could help expedite the delivery of new and safer therapies to people with lupus.
Aurinia Pharmaceuticals announced its plans for a single Phase III clinical trial for voclosporin in the treatment of lupus nephritis.
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
Neuropsychiatric lupus mainly affects children and young adults and can weaken cognitive functions. With a new non-invasive imaging technique, the damage can now be studied.